Abstract
The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone, and it has the ability to decrease blood sugar levels in a glucose-dependent nature to increase the secretion of insulin, and consequently, it reduces hyperglycaemia in T2D. GLP-1 has a half-life of about 1.5 minutes and is rapidly proteolytic degraded by dipeptidyl peptidase-4 (DPP-4). But GLP-1 receptor agonist (GLP-1R) works like GLP-1 but last much longer. GLP-1R control glycemia via glucose-dependent mechanisms of action and promote weight loss in obese and diabetic individuals. It also suppresses inappropriately elevated glucagon levels, both in fasting and postprandial states, slows gastric emptying, and decreases appetite. It reduces glycosylated hemoglobin (HbA1c) and fasting plasma glucose levels. It is associated with weight loss, and reductions in blood pressure with a low risk of hypoglycaemia. It is generally recommended as second- and third-line therapy for T2D. In this study an attempt has been taken to discuss aspects of GLP-1R in briefly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
